This HTML5 document contains 70 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n10http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q56688854
rdf:type
wikibase:Item
schema:description
article scientifique publié en 2005 im August 2005 veröffentlichter wissenschaftlicher Artikel wetenschappelijk artikel scientific article published on 11 July 2005 2005 թվականի հուլիսի 11-ին հրատարակված գիտական հոդված artículu científicu espublizáu en xunetu de 2005 наукова стаття, опублікована в серпні 2005
p:P577
wds:Q56688854-09828A9A-3E51-4CAD-93BB-CDCE56A9DA29
wdt:P577
2005-07-11T00:00:00Z
p:P407
wds:Q56688854-43ADD9AF-DFA3-438F-BF00-A6DA93AA1B92
wdt:P407
wd:Q1860
p:P2093
wds:Q56688854-914C99CF-505E-4209-93E0-D0D21F0256CF wds:Q56688854-5C62777C-DDF0-44F9-9AEE-45802F378AB0 wds:Q56688854-710C193F-B321-4485-8D8D-EC57643FFD52 wds:Q56688854-DAC19A2B-2C94-4C03-A7E9-F2E30CD13053 wds:Q56688854-D4BDE19D-5748-4300-8E61-85238A9664F1 wds:Q56688854-BFC2F7BC-48D6-450D-AB5E-678C20E5F150 wds:Q56688854-FFBADF6C-4059-4BE3-9A4F-EF5EA233BA4C wds:Q56688854-E839FB51-910A-414C-99E1-88BAED026B7C wds:Q56688854-EFE53F00-5913-4E1F-8183-F4F7A1352C10
wdt:P2093
José Baselga Ricardo Hitt Andreas Harstrick Jean Bourhis Jacques Tortochaux Pere Gascón Nadia Amellal José M Trigo Hernán Cortés-Funes
rdfs:label
Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head
skos:prefLabel
Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head
schema:name
Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head
p:P50
wds:Q56688854-D180D6E4-B53A-4A86-B6A6-808141E71D50
wdt:P50
wd:Q64901088
p:P1476
wds:Q56688854-BF9A244D-BB23-47FA-AD7F-A67518EE823A
wdt:P1476
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck
p:P304
wds:Q56688854-24BB9515-CB42-4CDC-9562-36FDE49B14D2
wdt:P304
5568-5577
p:P31
wds:Q56688854-FE8D7A5E-3A43-4554-8CDC-73E90C026479
wdt:P31
wd:Q13442814
p:P921
wds:Q56688854-53476C88-6895-4C6D-B118-8B8FF8005BC8 wds:Q56688854-202F1F0F-4752-4D0C-96FC-82AF4229111E wds:Q56688854-D7782F08-3AF2-4C44-91D1-445A11C15435 wds:Q56688854-E2E1E07B-1890-4737-BA9B-FDDBDAEAA779 wds:Q56688854-CC06E2AE-B553-4C0C-93A8-619CAC8FD9DD wds:Q56688854-A747AC6C-5F12-44B4-87BC-6D259DDA62D2 wds:Q56688854-72D58B12-529D-4D38-AB4E-8F409404C82D
wdt:P921
wd:Q420296 wd:Q79460 wd:Q181600 wd:Q974135 wd:Q422248 wd:Q880 wd:Q681817
p:P698
wds:Q56688854-BC9EEB22-6B32-4285-9828-EB8174785001
wdtn:P698
n12:16009950
wdt:P698
16009950
p:P1433
wds:Q56688854-74CF368A-FE30-4BB3-9D46-967B53C5F73B
wdt:P1433
wd:Q400292
p:P433
wds:Q56688854-1109B992-2223-48D3-9199-1E7DF84F0C95
p:P478
wds:Q56688854-E24E51A5-D45B-4397-833E-3B1FF252AEF7
wdt:P433
24
wdt:P478
23
p:P356
wds:Q56688854-4FD9204F-C845-4CC6-B123-D451392ED0F6
wdtn:P356
n10:JCO.2005.07.119
wdt:P356
10.1200/JCO.2005.07.119